

4 September 2009

Proposed chemical additions to the 2009/10 Multi-product Tender

PHARMAC has amended the list of chemicals it proposes to include in the Invitation to Tender 2009/10 by adding the chemicals set out below. The proposal to include these additional chemicals in the 2009/10 Invitation to Tender would be as set out in the 21 August 2009 consultation on the proposed 2009/10 Multi-product Tender list, and PHARMAC would also consider any Alternative Commercial Proposals (ACPs) in accordance with the consultation issued on 21 August 2009.

The proposed additional line items and the respective markets to be tendered in the 2009/10 Invitation to Tender are:

Chemical	Line Item	Market	Proposed DV Limit
Imatinib mesylate	Tab 100 mg	Community and Hospital	1%
Lopinavir with ritonavir	Tab 200 mg with ritonavir 50 mg	Community and Hospital	1%
Lopinavir with ritonavir	Oral liq 80 mg per ml	Community and Hospital	1%
Olanzapine	Orodispersible 5 mg	Hospital	5%
Olanzapine	Orodispersible 10 mg	Hospital	5%
Olanzapine	Tab 2.5 mg	Hospital	5%
Olanzapine	Tab 5 mg	Hospital	5%
Olanzapine	Tab 10 mg	Hospital	5%

Please note the Tender Agreement for imatinib mesylate and lopinavir with ritonavir may be subject to a Special Authority restriction.

Feedback sought

PHARMAC welcomes feedback on the proposed additional chemicals. Please submit ACPs by **5 pm Friday 25 September 2009** or alternatively provide feedback by **5 pm Friday 2 October 2009**, either in writing to:

Yvonne Chen
 Tender Analyst
 PHARMAC
 PO Box 10 254
 Wellington 6143

Email: yvonne.chen@pharmac.govt.nz

Fax: 04 460 4995

All feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC, and will be considered by the PHARMAC Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

Background

PHARMAC's consultation on the 2009/10 Multi-product Tender issued 21 August 2009 currently seeks feedback from various parties on:

- A proposal to tender certain pharmaceuticals for sole supply;
- The draft process and terms and conditions for the Invitation to Tender 2009/10; and
- Commercial Proposals as an alternative to tendering (for pharmaceutical suppliers and interested parties).

The 2009/10 Invitation to Tender is still in the drafting stage; and it will be finalised later in the year.

The proposed addition of imatinib, lopinavir with ritonavir and olanzapine in the 2009/10 Invitation to Tender is now reflected in the electronic version of the 21 August 2009 consultation letter currently available on our website, www.pharmac.govt.nz/suppliers/proposals/tenders.